CY1109585T1 - Υποκατεστημενες σπειροβενζαζεπινες - Google Patents

Υποκατεστημενες σπειροβενζαζεπινες

Info

Publication number
CY1109585T1
CY1109585T1 CY20091101295T CY091101295T CY1109585T1 CY 1109585 T1 CY1109585 T1 CY 1109585T1 CY 20091101295 T CY20091101295 T CY 20091101295T CY 091101295 T CY091101295 T CY 091101295T CY 1109585 T1 CY1109585 T1 CY 1109585T1
Authority
CY
Cyprus
Prior art keywords
cardiac
angiopressin
hypertension
formula
treatment
Prior art date
Application number
CY20091101295T
Other languages
English (en)
Inventor
Mona Patel
Philip J Rybczynski
Min Amy Xiang
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of CY1109585T1 publication Critical patent/CY1109585T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η εφεύρεση κατευθύνεται σε υποκατεστημένες βενζαζεπίνες μη-πεπτίδιο του Τύπου (I), που είναι χρήσιμες ως ανταγωνιστές υποδοχέα αγγειοπιεσίνης για θεραπεία καταστάσεων που συνδυάζονται με δραστικότητα υποδοχέα αγγειοπιεσίνης, όπως αυτές που περιλαμβάνουν αυξημένη αγγειακή αντίσταση και καρδιακή ανεπάρκεια, συμπεριλαμβανομένης συμφορητικής καρδιακής ανεπάρκειας, υπονατραιμίας και υπέρτασης, μεταξύ άλλων αποκαλυπτόμενες. Φαρμακευτικές συνθέσεις που περιλαμβάνουν μία ένωση του Τύπου (I) και μέθοδοι θεραπείας καταστάσεων, όπως υπέρτασης, συμφορητικής καρδιακής ανεπάρκειας, καρδιακής ανεπάρκειας, αγγειόσπασμο στεφανιαίας, καρδιακής ισχαιμίας, κίρρωσης του ήπατος, υπονατραιμίας, νεφρικού αγγειόσπασμου, νεφρικής ανεπάρκειας, διαβητικής νεφροπάθειας, εγκεφαλικού οιδήματος, εγκεφαλικής ισχαιμίας, συμφόρησης, θρόμβωσης ή κατακράτησης ύδατος, αποκαλύπτονται επίσης.
CY20091101295T 2003-06-17 2009-12-11 Υποκατεστημενες σπειροβενζαζεπινες CY1109585T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47937803P 2003-06-17 2003-06-17
EP04809449A EP1633719B1 (en) 2003-06-17 2004-06-16 Substituted spirobenzazepines

Publications (1)

Publication Number Publication Date
CY1109585T1 true CY1109585T1 (el) 2014-08-13

Family

ID=34465052

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091101295T CY1109585T1 (el) 2003-06-17 2009-12-11 Υποκατεστημενες σπειροβενζαζεπινες

Country Status (30)

Country Link
US (2) US20040266752A1 (el)
EP (1) EP1633719B1 (el)
JP (1) JP5252614B2 (el)
KR (1) KR101086246B1 (el)
CN (1) CN100467454C (el)
AR (1) AR044782A1 (el)
AT (1) ATE444953T1 (el)
AU (1) AU2004281257C1 (el)
BR (1) BRPI0411598A (el)
CA (1) CA2529649C (el)
CL (1) CL2004001507A1 (el)
CR (1) CR8168A (el)
CY (1) CY1109585T1 (el)
DE (1) DE602004023501D1 (el)
DK (1) DK1633719T3 (el)
EA (1) EA011089B1 (el)
ES (1) ES2332724T3 (el)
HR (2) HRP20051006A2 (el)
IL (1) IL172630A (el)
ME (1) ME00320B (el)
NO (1) NO20060247L (el)
NZ (1) NZ544180A (el)
PL (1) PL1633719T3 (el)
PT (1) PT1633719E (el)
RS (1) RS20050930A (el)
SI (1) SI1633719T1 (el)
TW (1) TWI354555B (el)
UA (1) UA82236C2 (el)
WO (1) WO2005037795A2 (el)
ZA (1) ZA200600430B (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044781A1 (es) * 2003-06-17 2005-10-05 Janssen Pharmaceutica Nv Proceso para la preparacion de derivados de espirobenzoazepinas substituidos no peptidicos y de composiciones farmaceuticas que los contienen.
JP2009523806A (ja) * 2006-01-20 2009-06-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ （４ｒ）−１−［４−（２−クロロ−５−フルオロベンゾイル）アミノ−３−メトキシベンゾイル］−１，２，３，５−テトラヒドロ−スピロ［４ｈ−１−ベンズアゼピン−４，１’−［２］シクロペンテン］−３’−カルボン酸の新規固体形態物
CA2665849A1 (en) 2006-09-22 2008-03-27 Janssen Pharmaceutica N.V. Spiro benzazepines used as vasopressin antagonists
US7825111B2 (en) 2006-09-22 2010-11-02 Janssen Pharmaceutica Nv Substituted spiroheterocycles
AR066834A1 (es) * 2007-06-06 2009-09-16 Janssen Pharmaceutica Nv Espirobenzoazepanos como antagonistas de vasopresina, composiciones farmaceuticas que los contienen, proceso de preparacion y usos para el tratamiento de afecciones cardiacas, renales y del sistema nervioso central.
CN101854932A (zh) * 2007-11-07 2010-10-06 詹森药业有限公司 包含血管紧张素转化酶抑制剂和加压素受体拮抗剂的组合疗法
WO2014062888A1 (en) 2012-10-18 2014-04-24 University Of South Florida Compositions and methods for treating stroke
PL2940008T3 (pl) 2012-12-26 2017-10-31 Sanwa Kagaku Kenkyusho Co Nowa pochodna benzoazepiny i jej zastosowanie farmaceutyczne

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617302A (en) * 1984-10-15 1986-10-14 Eli Lilly And Company Inotropic agents
WO1991005549A1 (en) 1989-10-20 1991-05-02 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5985869A (en) * 1989-10-20 1999-11-16 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5849780A (en) * 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
JPH08502474A (ja) * 1992-10-07 1996-03-19 メルク エンド カンパニー インコーポレーテッド トコリティックオキシトシンレセプターアンタゴニスト
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
KR100374924B1 (ko) * 1994-04-22 2003-07-22 퀸스 유니버시티 엣 킹스톤 남성발기기능장애를회복시키고진단하기위한설하용량형
US5753648A (en) 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
JP3282494B2 (ja) * 1995-05-16 2002-05-13 富士ゼロックス株式会社 画像定着装置
US5753715A (en) * 1995-06-02 1998-05-19 Ortho Pharmaceutical Corporation 2-disubstituted cyclohexenyl and cyclohexyl antimicrobial agents
US5726723A (en) * 1996-01-31 1998-03-10 Technology Research International Corporation Sub-twisted nematic liquid crystal display
AUPP150098A0 (en) 1998-01-27 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
ATE305454T1 (de) * 2000-07-05 2005-10-15 Ortho Mcneil Pharm Inc Nichtpeptidische substituierte spirobenzoazepine als vasopressin antagonisten
AR044781A1 (es) 2003-06-17 2005-10-05 Janssen Pharmaceutica Nv Proceso para la preparacion de derivados de espirobenzoazepinas substituidos no peptidicos y de composiciones farmaceuticas que los contienen.

Also Published As

Publication number Publication date
ZA200600430B (en) 2009-08-26
KR101086246B1 (ko) 2011-11-23
RS20050930A (en) 2008-04-04
NZ544180A (en) 2009-01-31
ME00320B (me) 2011-05-10
SI1633719T1 (sl) 2010-01-29
CL2004001507A1 (es) 2005-05-27
AR044782A1 (es) 2005-10-05
AU2004281257A1 (en) 2005-04-28
ATE444953T1 (de) 2009-10-15
NO20060247L (no) 2006-03-13
EA200501831A1 (ru) 2006-06-30
WO2005037795A2 (en) 2005-04-28
EA011089B1 (ru) 2008-12-30
EP1633719A2 (en) 2006-03-15
CN100467454C (zh) 2009-03-11
CA2529649A1 (en) 2005-04-28
US20040266752A1 (en) 2004-12-30
CN1835925A (zh) 2006-09-20
DE602004023501D1 (de) 2009-11-19
CR8168A (es) 2008-09-10
MEP49108A (en) 2011-02-10
AU2004281257B2 (en) 2010-02-04
JP2007521272A (ja) 2007-08-02
WO2005037795A3 (en) 2005-07-28
IL172630A0 (en) 2006-04-10
AU2004281257C1 (en) 2010-07-01
CA2529649C (en) 2012-01-31
JP5252614B2 (ja) 2013-07-31
TWI354555B (en) 2011-12-21
TW200515911A (en) 2005-05-16
EP1633719B1 (en) 2009-10-07
PT1633719E (pt) 2009-11-11
KR20060023157A (ko) 2006-03-13
ES2332724T3 (es) 2010-02-11
HRP20090606T1 (hr) 2010-01-31
HRP20051006A2 (en) 2006-05-31
IL172630A (en) 2011-10-31
US20070179128A1 (en) 2007-08-02
US7687494B2 (en) 2010-03-30
UA82236C2 (en) 2008-03-25
DK1633719T3 (da) 2010-01-04
PL1633719T3 (pl) 2010-03-31
BRPI0411598A (pt) 2006-08-29

Similar Documents

Publication Publication Date Title
CY1109585T1 (el) Υποκατεστημενες σπειροβενζαζεπινες
NO20060195L (no) Kinolylamidderivater som CCR-5-antagonister
CY1112628T1 (el) Νεοι αναστολεις κινασης
MY128065A (en) Tricyclic benzodiazepines as vasopressin receptor antagonists
DK2078022T3 (da) Spirobenzazepiner anvendt som vasopressinantagonister
DK0539086T3 (da) Kondenserede pyrimidinderivater og deres anvendelse som angiotensin II-antagonister
CY1106989T1 (el) Ενεργοποιητες γλυκοκινασης τυπου 5-υποκατεστημενης πυραζινης ή πυριδινης
CY1105603T1 (el) Συνεργιστικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της ρενινης, για καρδιαγγειακες νοσους
CY1108054T1 (el) Θεραπεια της δυσκινησιας μεσω ανταγωνιστων επιλεκτικων οπιουχων mu
CY1106746T1 (el) Χρηση του irbesartan για την προληψη ή τη θεραπεια της πνευμονικης υπερτασης
CY1112135T1 (el) Ανταγωνιστες υποδοχεα il-8
TR200000792T2 (tr) Vitronektin reseptör antagonistleri.
DK1307430T3 (da) Ikke-peptidsubstituerede spirobenzoazepiner som vasopressin-antagonister
DK1214323T3 (da) Indoloazepiner som vasopressinreceptorantagonister
WO2006049984A3 (en) Novel [1,4]benzodiazepines as vasopressin v2 receptor antagonists
YU32702A (sh) Nepeptidni supstituisani benzotiazepini kao antagonisti vazopresina
AR031858A1 (es) Espirobenzoazepinas sustituidas no peptidicas, composiciones farmaceuticas que las comprenden, uso de tales compuestos en la fabricacion de medicamentos, proceso para preparar dichas composiciones e intermediarios utiles en la preparacion de tales compuestos